Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Karyopharm Therapeutics Q3 EPS $(0.30) Misses $(0.28) Estimate, Sales $36.01M Miss $37.28M Estimate

Author: Benzinga Newsdesk | November 02, 2023 07:36am
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 33.33 percent increase over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $36.01 million which missed the analyst consensus estimate of $37.28 million by 3.41 percent. This is a 0.38 percent decrease over sales of $36.15 million the same period last year.

Posted In: KPTI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist